When was Auritec Pharma founded?

Auritec Pharma was founded in 2002 and raised its 1st funding round 7 years after it was founded.

Where is Auritec Pharma located?

Auritec Pharma is headquartered in Santa Monica, United States.

Who is the current CEO of Auritec Pharma?

Tom Smith of Auritec Pharma. They have also founded 1 company.

How many employees does Auritec Pharma have?

As of Dec 31, 2022, the latest employee count at Auritec Pharma is 7.

Is Auritec Pharma a funded company?

Auritec Pharma is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 23, 2009.

When was the latest funding round of Auritec Pharma?

Auritec Pharma's latest funding was a $***** Grant (prize money) round on May 18, 2012, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $413M in funding in 2026 to date.

Where does Auritec Pharma rank among its competitors?

Auritec Pharma ranks 49th amongst 67 active competitors, of which 17 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lightcast Discovery, which secured $49M in Aug, 2023.

Who are the top competitors of Auritec Pharma?

Auritec Pharma's top competitors include Lightcast Discovery, Slingshot Bioscience and HitGen. Among them, Lightcast Discovery secured the most recent funding round in August, 2023.

Auritec Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Auritec Pharmaceutical is a drug delivery company focused on women’s health. Its main product is an intravaginal ring (IVR) sustained release drug delivery system: VersaRing™. It has a large pipeline of programs in clinical and preclinical stage ranging from HIV, herpes, diabetes, to uterine fibroids, endometriosis, and many more. Versa is a technology platform for drug delivery that can deliver a broad range of drugs:-It focusses on FDA approved drugs used for the management of chronic conditions, that have large markets, and that have high potential to achieve therapeutic levels via vaginal delivery. Since its inception, Auritec has received over $20 million in NIH funding to develop sustained-release formulation for a number of serious or life-threatening diseases.

Key Metrics

Founded Year

2002

Location

Santa Monica, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), May 18, 2012, $*****

Investors

HHS

Ranked

49^th among 67 active competitors

Employee Count

7 as on Dec 31, 2022

Similar Companies

Lightcast Discovery & 69 more

View Auritec Pharma's full profile

Auritec Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Auritec Pharmaceuticals Inc CIN: 841629188 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2022)	-

Auritec Pharma has raised funding over 6 rounds. Its first funding round was on Feb 23, 2009. Its latest funding round was a Grant (prize money) round on May 18, 2012 for $*****. 1 investor participated in its latest round. Auritec Pharma has 1 institutional investor.

Here is the list of recent funding rounds of Auritec Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 18, 2012	7539262	Grant (prize money)	9541465	5611960	1730303	7747657
Feb 13, 2012	8420486	Grant (prize money)	7699762	4401572	2059958	HHS
Jul 15, 2011	5756671	Grant (prize money)	4503168	2646226	2153963	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Auritec Pharma's funding rounds and investors

The founders of Auritec Pharma is Tom Smith. Tom Smith is the CEO of Auritec Pharma.

Here are the details of Auritec Pharma's key team members:

Tom Smith: Founder & CEO of Auritec Pharma.
Contact Info: 1 email address

View details of Auritec Pharma's Founder profiles and Board Members

Auritec Pharma's employee count trend

Auritec Pharma has 7 employees as of Dec 22. The total employee count is the same as what it was in Dec 21. Here is Auritec Pharma's employee count trend over the years:

Uncover Auritec Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Auritec Pharma include Lightcast Discovery, Slingshot Bioscience and HitGen. Here is the list of Top 10 competitors of Auritec Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lightcast Discovery 2019, Cambridge (United Kingdom), Series B	Provider of advanced single-cell analysis solutions	$107M	M Ventures, The Sir Martin Wood Residue Trust ... & 19 others	61/100
2nd	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	56/100
3rd	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	Shiyu, CDH & 2 others	55/100
4th	InterAx Biotech 2016, Villigen (Switzerland), Series A	Arrestin-based biosensors and computational methods for GPCR based drug discovery	$3.19M	Verve Ventures, Venture Kick & 5 others	54/100
5th	StemoniX 2014, San Diego (United States), Acquired	Engineering human brain and nerve models for neurological insights	$33.7M	EvoNexus, Gopher Angels & 19 others	47/100
6th	Sequence Bio 2013, St John s (Canada), Seed	Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.	$5.47M	DCVC, Y Combinator & 5 others	45/100
7th	Vectus Biosystems 2005, Rosebery (Australia), Public	Develops drug discovery platform	-	-	45/100
8th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	Shanghai Changjiang Guohong Investment Management, SDIC Venture Capital Management ... & 3 others	41/100
9th	ZoBio 2004, Leiden (Netherlands), Acquired	Provider of fragment-based drug discovery services	-	Europa, Libertatis Ergo Holding	40/100
10th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	The Vertical Group, Kleiner Perkins & 10 others	40/100
49th	Auritec Pharma 2002, Santa Monica (United States), Funding Raised	Drug delivery company focused on women’s health.	-	HHS	19/100